|
|
Vaccine Detail
|
VHL16 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: VHL16 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007178
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- VHL
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Renal Cancer. A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL16 peptide, also known as S111I, is a point mutation variant of the VHL tumor suppressor protein; the mutation is in amino acid position 111. Vaccination with this agent may stimulate a cytotoxic T-cell response in patients with VHL-associated cancers that express this variant of the VHL tumor suppressor protein (NCI04) (NCIT_C2740).
|
| Host Response |
|
|
| References |
NCIT_C2740: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2740]
|
|
